Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.

CONCLUSIONS: This exploratory study showed that GBL levels increased, VEGF levels decreased, and CEC levels were suppressed during S-1 administration. S-1 appears to have anti-angiogenic activity. PMID: 23739924 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23739924?dopt=Abstract

Source: Clinical Breast Cancer - June 6, 2013 Category: Cancer & Oncology Authors: Tsuji W, Ishiguro H, Tanaka S, Takeuchi M, Ueno T, Toi M Tags: Int J Clin Oncol Source Type: research